170 related articles for article (PubMed ID: 16222183)
1. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
Myssiorek D; Tronco G
Laryngoscope; 2005 Oct; 115(10):1707-16. PubMed ID: 16222183
[TBL] [Abstract][Full Text] [Related]
2. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
3. 111Indium pentetreotide scan detection of familial paragangliomas.
Myssiorek D; Palestro CJ
Laryngoscope; 1998 Feb; 108(2):228-31. PubMed ID: 9473073
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
5. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck.
Duet M; Sauvaget E; Pételle B; Rizzo N; Guichard JP; Wassef M; Le Cloirec J; Herman P; Tran Ba Huy P
J Nucl Med; 2003 Nov; 44(11):1767-74. PubMed ID: 14602858
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
8. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
10. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and follow-up of head and neck paragangliomas. Contributions of nuclear medicine].
Tamayo Alonso P; Ruano Pérez R; Muñoz Herrera A
Acta Otorrinolaringol Esp; 2009 Feb; 60 Suppl 1():68-75. PubMed ID: 19245777
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
13. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
14. Octreotide scintigraphy in the head and neck.
Bustillo A; Telischi F; Weed D; Civantos F; Angeli S; Serafini A; Whiteman M
Laryngoscope; 2004 Mar; 114(3):434-40. PubMed ID: 15091215
[TBL] [Abstract][Full Text] [Related]
15. [Detection of somatostatin receptors in tumors in the area of the head and neck and their clinical importance].
Kau RJ; Wagner-Manslau C; Saumweber DM; Arnold W
Laryngorhinootologie; 1994 Jan; 73(1):21-6. PubMed ID: 7908199
[TBL] [Abstract][Full Text] [Related]
16. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
17. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
18. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
[TBL] [Abstract][Full Text] [Related]
19. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D
J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]